BoomRay Raises $43 Million for Novel Diagnostic/Therapeutic Radionuclide Medicines
publication date: Sep 6, 2022
Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. The company intends to focus on nuclear drugs for new targets plus vectors and platform technologies. It has already built a radionuclide drug development platform with the help of WuXi AppTec. The A Round was led by Sequoia Capital China, with participation from Riverhead Capital, Tianfu Sanjiang Asset Management, Puhua Capital, CTS Capital, Life Park Venture Fund and Shenzhen Jinshen Investment. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.